ProMIS Neurosciences Designates PMN330 as Third, Validated Lead Product for Development in Alzheimer’s Disease

13 sept. 2017 07h30 HE | Source: ProMIS Neurosciences Inc. ProMIS Neurosciences Inc.

TORONTO and CAMBRIDGE, Mass., Sept. 13, 2017 (GLOBE NEWSWIRE) -- ERN UK